Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT
- PMID: 28198519
- DOI: 10.5603/NMR.a2016.0043
Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT
Abstract
Background: Tumor hypoxia induces the expression of several genes via the hypoxia-inducible transcription factor-1 alpha (HIF-1a). It is associated with the prognosis of several cancers. We studied the immunohistochemical expression of HIF-1a in patients with invasive ductal cancer (IDC) of the breast and the possible correlation with the maximum standardized uptake value of the primary tumor (pSUVmax) as well as other biological parameters. Prognostic significance of pSUVmax and expression of HIF-1a for the prediction of progression-free survival (PFS) was also assessed.
Material and methods: Two-hundred seven female patients with IDC who underwent pretreatment fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) were enrolled. The pSUVmax was compared with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), axillary lymph node (LN) metastasis, stage and HIF-1a expression. The prognostic value of pSUVmax for PFS was assessed using the Kaplan-Meier method.
Results: pSUVmax was significantly higher in patients with HIF-1a expression ≥ 2 compared to patients with HIF-1a expression < 2 (5.2 ± 4.5 vs. 3.7 ± 3.1, p = 0.008). pSUVmax was also significantly higher in higher stage (p < 0.000001), ER-negative tumors (p < 0.0001), PR-negative tumors (p = 0.0011) and positive LN metastasis (p = 0.0013). pSUVmax was significantly higher in patients with progression compared to patients who were disease-free (6.8 ± 4.4 vs. 4.1 ± 3.7, p = 0.0005). A receiver-operating characteristic curve demonstrated a pSUVmax of 6.51 to be the optimal cutoff for predicting PFS (sensitivity: 53.6%, specificity: 86.0%). Patients with high pSUVmax (> 6.5) had significantly shorter PFS compared to patients with low pSUVmax (p < 0.0001).
Conclusions: pSUVmax on pretreatment F-18 FDG PET/ CT reflect expression of HIF-1a and can be used as a good surrogate marker for the prediction of progression in patients with IDC. The amount of FDG uptake is determined by the presence of glucose metabolism and hypoxia in breast cancer cell.
Keywords: F-18 FDG PET/CT; HIF-1α; Invasive ductal cancer of breast; SUVmax.
Similar articles
-
Predictive Value of 18F-FDG PET/CT for Axillary Lymph Node Metastasis in Invasive Ductal Breast Cancer.Ann Surg Oncol. 2017 Aug;24(8):2174-2181. doi: 10.1245/s10434-017-5860-0. Epub 2017 Apr 21. Ann Surg Oncol. 2017. PMID: 28432480
-
Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer.Nucl Med Mol Imaging. 2011 Jun;45(2):117-24. doi: 10.1007/s13139-011-0081-0. Epub 2011 Apr 20. Nucl Med Mol Imaging. 2011. PMID: 24899990 Free PMC article.
-
18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.J Nucl Med. 2012 Sep;53(9):1337-44. doi: 10.2967/jnumed.111.098640. Epub 2012 Jun 29. J Nucl Med. 2012. PMID: 22870824
-
The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer.Eur J Radiol. 2018 Aug;105:1-7. doi: 10.1016/j.ejrad.2018.05.014. Epub 2018 May 17. Eur J Radiol. 2018. PMID: 30017264 Review.
-
Biological characterisation of breast cancer by means of PET.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S80-7. doi: 10.1007/s00259-004-1529-6. Epub 2004 May 4. Eur J Nucl Med Mol Imaging. 2004. PMID: 15127240 Review.
Cited by
-
The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.EJNMMI Res. 2023 Jan 23;13(1):5. doi: 10.1186/s13550-023-00953-y. EJNMMI Res. 2023. PMID: 36689007 Free PMC article. Review.
-
Affinity of PET-MRI Tracers for Hypoxic Cells in Breast Cancer: A Systematic Review.Cells. 2024 Jun 17;13(12):1048. doi: 10.3390/cells13121048. Cells. 2024. PMID: 38920676 Free PMC article.
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2733-2743. doi: 10.1007/s00259-024-06683-0. Epub 2024 Apr 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587643 Free PMC article. Clinical Trial.
-
Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses.J Gastric Cancer. 2017 Dec;17(4):384-393. doi: 10.5230/jgc.2017.17.e43. Epub 2017 Dec 28. J Gastric Cancer. 2017. PMID: 29302378 Free PMC article.
-
[18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis.EJNMMI Res. 2025 Feb 27;15(1):17. doi: 10.1186/s13550-025-01205-x. EJNMMI Res. 2025. PMID: 40014192 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous